Frontiers in Oncology

Cell Transfer Immunotherapy for Cancer

Steven Rosenberg, MD, PhD
Tuesday, November 3, 2020

Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. He is also a Professor in the Department of Laboratory Medicine at the Karolinska Institutet in Stockholm, Sweden.

Dr. Rosenberg pioneered the first effective immunotherapies for patients with advanced cancer. His basic and clinical studies of interleukin-2 directly resulted in the approval of this immunotherapy by the US Food and Drug Administration for the treatment of patients with metastatic melanoma and renal cancer, many of whom remain disease-free over 25 years after treatment. His studies of cell transfer immunotherapy resulted in durable complete remissions in patients with metastatic melanoma and were the first to directly demonstrate the role of T lymphocytes in human cancer immunotherapy. He pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His studies of the adoptive transfer of genetically modified lymphocytes were the first to result in the regression of metastatic cancer including patients with melanoma and sarcomas. He was the first to demonstrate the effectiveness of genetically engineered CAR-T cells to mediate the regression of B-cell malignancies in humans, a treatment now approved by the FDA for widespread use. In recent work Dr. Rosenberg established new approaches for the application of immunotherapy to patients with a variety of common solid cancers by targeting the unique mutations present in the patient’s cancer.

Frontiers in Oncology

Frontiers in Oncology, a recurring seminar series organized by the Stanford Cancer Institute, is designed to highlight innovations in cancer research across the spectrum of basic, translational, clinical and population science.  The dynamic speakers represent a broad range of disciplines and expertise from both Stanford faculty and national thought leaders.  The audience for this seminar series includes Stanford faculty, trainees and staff as well as anyone in the broader community with an interest in cancer research.  Each recorded seminar is approximately 1 hour in length.